miRNA-mRNA integrative analysis in primary myelofibrosis CD34+cells: Role of miR-155/JARID2 axis in abnormal megakaryopoiesis

Blood

Volumn 124, Issue 13, 2014, Pages e21-e32

  Norfo, Ruggiero ^a   Zini, Roberta ^a   Pennucci, Valentina ^a   Bianchi, Elisa ^a   Salati, Simona ^a   Guglielmelli, Paola ^b   Bogani, Costanza ^b   Fanelli, Tiziana ^b   Mannarelli, Carmela ^b   Rosti, Vittorio ^c   Pietra, Daniela ^d   Salmoiraghi, Silvia ^e   Bisognin, Andrea ^f   Ruberti, Samantha ^a   Rontauroli, Sebastiano ^a   Sacchi, Giorgia ^a   Prudente, Zelia ^a   Barosi, Giovanni ^c   Cazzola, Mario ^d   Rambaldi, Alessandro ^e   Bortoluzzi, Stefania ^f   Ferrari, Sergio ^a   Tagliafico, Enrico ^a   Vannucchi, Alessandro M ^b   Manfredini, Rossella ^a   more..

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e Hospital Papa Giovanni XXIII   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FGR PROTEIN; FIBRINOGEN RECEPTOR; HIGH MOBILITY GROUP B3 PROTEIN; JARID2 PROTEIN; MICRORNA 155; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NUCLEAR RECEPTOR NR4A3; OLFM4 PROTEIN; PROTEIN CDC42; TUMOR MARKER; UNCLASSIFIED DRUG; CD34 ANTIGEN; JARID2 PROTEIN, HUMAN; MESSENGER RNA; MICRORNA; MIRN155 MICRORNA, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ARTICLE; CANCER PATIENT; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC ASSOCIATION; HEMATOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MYELOID METAPLASIA; PROTEIN RNA BINDING; RNA ANALYSIS; TRANSCRIPTION REGULATION; CELL DIFFERENTIATION; CELL LINEAGE; CYTOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENE SILENCING; GENETICS; GRANULOCYTE; HEMATOPOIETIC STEM CELL; METABOLISM; REPRODUCIBILITY; RNA INTERFERENCE; THROMBOCYTOPOIESIS;

ANTIGENS, CD34; CELL DIFFERENTIATION; CELL LINEAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENE SILENCING; GRANULOCYTES; HEMATOPOIETIC STEM CELLS; HUMANS; MEGAKARYOCYTES; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 2; PRIMARY MYELOFIBROSIS; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, MESSENGER; THROMBOPOIESIS;

EID: 84907487389     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-544197     Document Type: Article

References (46)

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-191.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
4. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
5. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-1735.
6. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861-1869.
7. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
8. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
9. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654):83-86.
10. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 2003;113(1):25-36.
11. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005;33(4):1290-1297.
12. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854.
13. Gordon JE, Wong JJ, Rasko JE. MicroRNAs in myeloid malignancies. Br J Haematol. 2013;162(2):162-176.
14. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143-159.
15. Guglielmelli P, Tozzi L, Pancrazzi A, et al MPD Research Consortium. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol. 2007;35(11):1708-1718.
16. Slezak S, Jin P, Caruccio L, et al. Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. J Transl Med. 2009;7:39.
17. Lin X, Rice KL, Buzzai M, et al. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation. Leukemia. 2013;27(2):344-352.
18. Zhan H, Cardozo C, Yu W, et al. MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells Mol Dis. 2013;50(3):190-195.
19. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
20. Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114(8):1477-1483.
21. Salati S, Zini R, Bianchi E, et al. Role of CD34 antigen in myeloid differentiation of human hematopoietic progenitor cells. Stem Cells. 2008;26(4):950-959.
22. Zini R, Norfo R, Ferrari F, et al. Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression. Exp Hematol. 2012;40(12):1043-1054.e6.
23. Tenedini E, Roncaglia E, Ferrari F, et al. Integrated analysis of microRNA and mRNA expression profiles in physiological myelopoiesis: role of hsa-mir-299-5p in CD341 progenitor cells commitment. Cell Death Dis. 2010;1:e28.
24. Guglielmelli P, Zini R, Bogani C, et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells. 2007;25(1):165-173.
25. Schotte D, Pieters R, Den Boer ML. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia. 2012;26(1):1-12.
26. Deng H, Guo Y, Song H, et al. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 2013;518(2):351-359.
27. Li H, Zhao H, Wang D, Yang R. microRNA regulation in megakaryocytopoiesis. Br J Haematol. 2011;155(3):298-307.
28. O'Connell RM, Zhao JL, Rao DS. MicroRNA function in myeloid biology. Blood. 2011;118(11):2960-2969.
29. Ramirez-Herrick AM, Mullican SE, Sheehan AM, Conneely OM. Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice. Blood. 2011;117(9):2681-2690.
30. Yang L, Wang L, Kalfa TA, et al. Cdc42 critically regulates the balance between myelopoiesis and erythropoiesis. Blood. 2007;110(12):3853-3861.
31. Puda A, Milosevic JD, Berg T, et al. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol. 2012;87(3):245-250.
32. Nemeth MJ, Kirby MR, Bodine DM. Hmgb3 regulates the balance between hematopoietic stem cell self-renewal and differentiation. Proc Natl Acad Sci USA. 2006;103(37):13783-13788.
33. Bianchi E, Zini R, Salati S, et al. c-myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression. Blood. 2010;116(22):e99-e110.
34. Hussein K, Theophile K, Dralle W, Wiese B, Kreipe H, Bock O. MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia. Platelets. 2009;20(6):391-400.
35. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123-e133.
36. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176-2184.
37. Konopleva M, Mikhail A, Estrov Z, et al. Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood. 1999;93(5):1668-1676.
38. Dos Santos C, McDonald T, Ho YW, et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood. 2013;122(11):1900-1913.
39. Shpilman M, Niv-Spector L, Katz M, et al. Development and characterization of high affinity leptins and leptin antagonists. J Biol Chem. 2011;286(6):4429-4442.
40. Tokuhisa Y, Lidsky ME, Toshimitsu H, et al. Src family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma. Ann Surg Oncol. 2014;21(3):1024-1030.
41. Lemoli RM, Salvestrini V, Bianchi E, et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood. 2009;114(25):5191-5200.
42. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol. 2013;14(8):475-488.
43. Peng JC, Valouev A, Swigut T, et al. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell. 2009;139(7):1290-1302.
44. Kitajima K, Kojima M, Nakajima K, et al. Definitive but not primitive hematopoiesis is impaired in Jumonji mutant mice. Blood. 1999;93(1):87-95.
45. O'Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 2008;205(3):585-594.
46. Balduini A, Badalucco S, Pugliano MT, et al. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes. PLoS ONE. 2011;6(6):e21015.